Form D · Pharmaceuticals
Eumentis Therapeutics, Inc.
Newton, MA · CIK 0001823359
Offering snapshot reported Jun 26, 2024 · SEC filing
- Reported sold
- $765K Offering amount: $2M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $20K Reported outside-investor minimum
- First sale
- Aug 16, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 26, 2024 | Initial | $765,000 | No comparison | 11 | SEC filing |
| Mar 17, 2023 | Initial | Yet to sell | No comparison | 1 | SEC filing |
| Apr 15, 2022 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
| Sep 2, 2020 | Initial | $1,500,000 | No comparison | 25 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-516970
The company has closed the offering.
Source: Form D, filed Jun 26, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Maryann Bryla | Director |
| Amar Kapur | Director |
| James Larrick | Director |
| Randall Marshall | Executive |
| Kim Patrick | Director |
| Andrew Pearlman | Director |
| Mark Tepper | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
508 Dudley Road Suite 105
Newton, MA, 02459
Newton, MA, 02459